Alexandre Piccini

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) are remarkably effective inducing deep molecular remission in most patients. However, they are less(More)
  • 1